혹시 aston pd(으)로 찾으셨나요?

블로그

• A phase 1b/2, open-label study of adrixetinib (Q702) in combination with intravenous pembrolizumab orally administrated novel Axl/Mer/CSF1R tyrosine kinase inhibitor for which the primary mechanism of action -1/PD-L1 treatment. blog.naver.com · 2025.06.03